Theravance and GlaxoSmithKline received approval in Europe to market Relvar, a combination of corticosteroid and a long-acting beta-agonist, as a treatment for both chronic obstructive pulmonary disease and asthma. The approval gives GSK the right to collect a $15 million milestone fee from Theravance and another $15 million when the drug is commercialized.

Full Story:

Related Summaries